NuCana plc (NASDAQ: NCNA)

NuCana plc, a clinical-stage biopharmaceutical company listed on the NASDAQ stock exchange under the symbol NCNA, is dedicated to improving treatment outcomes for patients with cancer. The company's primary business activities involve the development of novel anti-cancer therapies, utilizing its proprietary ProTide technology to transform nucleoside analogs into more effective and safer medicines.

NuCana's ProTide technology is a unique approach that converts nucleoside analogs into activated nucleotide analogs with a phosphate group, which is protected by specific combinations of aryl, ester, and amino acid groupings. This innovative phosphoramidate chemistry is the key to the ProTide technology, and NuCana has licensed what it believes to be the foundational patent estate for the application of phosphoramidate chemistry in oncology.

The company's primary products are NUC-3373 and NUC-7738, which are being developed as treatments for patients with advanced solid tumors and hematological malignancies. NUC-3373 is a ProTide transformation of the nucleoside analog 5-fluorouracil (5-FU), widely used in the treatment of various cancers. NUC-3373 has shown promising results in clinical trials, including high levels of the active anti-cancer metabolite inside cancer cells and a favorable pharmacokinetic and safety profile. NUC-7738, on the other hand, is a ProTide transformation of the nucleoside analog 3'-deoxyadenosine (3'-dA), which has shown potent anti-cancer activity in preclinical studies.

NuCana's business model is focused on developing and commercializing its ProTide technology platform, which has the potential to address unmet medical needs in oncology. The company's strategy includes rapidly developing NUC-3373 to replace 5-FU as the standard of care for the treatment of patients with colorectal cancer, identifying additional indications for development of NUC-3373, rapidly developing NUC-7738 as a treatment for patients with solid tumors, leveraging its proprietary ProTide technology platform to develop additional product candidates, and building a focused commercial organization.

NUC-3373 has a favorable safety and pharmacokinetic profile, with a long plasma half-life of 6 to 14 hours, allowing for a shorter infusion time of 30 minutes to four hours compared to the 46-hour continuous infusion required with 5-FU. The company has reported encouraging signs of efficacy in a Phase 1 clinical trial, with several patients achieving longer periods of progression-free survival (PFS) than those achieved on previous regimens. NUC-3373 is currently being evaluated in three ongoing clinical trials: a Phase 1b/2 trial in patients with metastatic colorectal cancer, a randomized Phase 2 clinical trial in patients with advanced colorectal cancer, and a Phase 1b/2 modular trial in patients with solid tumors and lung cancer.

NUC-7738 is a ProTide transformation of 3'-deoxyadenosine, or 3'-dA, a nucleoside analog that was originally isolated from the fungus Cordyceps sinensis in 1950. NUC-7738 is designed to generate the active anti-cancer metabolite, 3'-dATP, directly inside cancer cells, bypassing the key limitations associated with breakdown, transportation, and activation of 3'-dA. NUC-7738 has shown greater anti-cancer activity than 3'-dA in preclinical studies and is currently being evaluated in a Phase 1/2 clinical trial in patients with advanced solid tumors.

Acelarin, a ProTide transformation of gemcitabine, is a nucleoside analog used as a chemotherapeutic to treat a wide range of tumors. Acelarin has been designed to overcome the key limitations associated with gemcitabine, including breakdown, active transport, and activation within the cancer cell. Acelarin has shown anti-cancer activity in patients with platinum-resistant ovarian cancer and is currently being evaluated in a Phase 3 clinical trial in patients with locally advanced or metastatic biliary tract cancer.

NuCana's ProTide technology has several advantages over traditional nucleoside analogs. First, ProTides are designed to generate the active anti-cancer metabolite directly inside cancer cells, bypassing the key limitations associated with breakdown, transportation, and activation of traditional nucleoside analogs. Second, ProTides are more stable and have a longer half-life than traditional nucleoside analogs, which can lead to improved efficacy and reduced toxicity. Third, ProTides can be designed to target specific biomarkers or molecular profiles, which can help to identify patients who are most likely to benefit from treatment.